These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38265267)

  • 1. EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas.
    DuCote TJ; Song X; Naughton KJ; Chen F; Plaugher DR; Childress AR; Gellert AR; Skaggs EM; Qu X; Liu J; Liu J; Li F; Wong KK; Brainson CF
    Cancer Res Commun; 2024 Feb; 4(2):388-403. PubMed ID: 38265267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas.
    DuCote TJ; Song X; Naughton KJ; Chen F; Plaugher DR; Childress AR; Edgin AR; Qu X; Liu J; Liu J; Li F; Wong KK; Brainson CF
    bioRxiv; 2023 Jun; ():. PubMed ID: 37333199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
    Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
    Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-101 regulates autophagy, proliferation and apoptosis via targeting EZH2 in laryngeal squamous cell carcinoma.
    Chen L; Jia J; Zang Y; Li J; Wan B
    Neoplasma; 2019 Jul; 66(4):507-515. PubMed ID: 30868890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
    Quan C; Chen Y; Wang X; Yang D; Wang Q; Huang Y; Petersen RB; Liu X; Zheng L; Li Y; Huang K
    Cancer Lett; 2020 Dec; 495():41-52. PubMed ID: 32920200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
    Sun S; Yu F; Xu D; Zheng H; Li M
    Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
    Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
    J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
    Qiu J; Sharma S; Rollins RA; Paul TA
    Future Med Chem; 2020 Aug; 12(15):1415-1430. PubMed ID: 32723083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA SOX2-OT facilitates laryngeal squamous cell carcinoma development by epigenetically inhibiting PTEN via methyltransferase EZH2.
    Tai Y; Ji Y; Liu F; Zang Y; Xu D; Ma S; Qin L; Ma J
    IUBMB Life; 2019 Sep; 71(9):1230-1239. PubMed ID: 30811870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.
    Zhou L; Mudianto T; Ma X; Riley R; Uppaluri R
    Clin Cancer Res; 2020 Jan; 26(1):290-300. PubMed ID: 31562203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsa_circ_0006232 promotes laryngeal squamous cell cancer progression through FUS-mediated EZH2 stabilization.
    Wu T; Wang G; Zeng X; Sun Z; Li S; Wang W; Yu B
    Cell Cycle; 2021 Sep; 20(18):1799-1811. PubMed ID: 34437823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.
    Zhao Y; Wang XX; Wu W; Long H; Huang J; Wang Z; Li T; Tang S; Zhu B; Chen D
    Biochem Biophys Res Commun; 2019 Sep; 517(2):201-209. PubMed ID: 31331645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
    Zingg D; Arenas-Ramirez N; Sahin D; Rosalia RA; Antunes AT; Haeusel J; Sommer L; Boyman O
    Cell Rep; 2017 Jul; 20(4):854-867. PubMed ID: 28746871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.
    Xiao Q; Zheng F; Tang Q; Wu JJ; Xie J; Huang HD; Yang XB; Hann SS
    Cell Physiol Biochem; 2018; 49(4):1615-1632. PubMed ID: 30223276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-340 impedes the progression of laryngeal squamous cell carcinoma by targeting EZH2.
    Yu W; Zhang G; Lu B; Li J; Wu Z; Ma H; Wang H; Lian R
    Gene; 2016 Feb; 577(2):193-201. PubMed ID: 26656176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
    Zhang H; Qi J; Reyes JM; Li L; Rao PK; Li F; Lin CY; Perry JA; Lawlor MA; Federation A; De Raedt T; Li YY; Liu Y; Duarte MA; Zhang Y; Herter-Sprie GS; Kikuchi E; Carretero J; Perou CM; Reibel JB; Paulk J; Bronson RT; Watanabe H; Brainson CF; Kim CF; Hammerman PS; Brown M; Cichowski K; Long H; Bradner JE; Wong KK
    Cancer Discov; 2016 Sep; 6(9):1006-21. PubMed ID: 27312177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
    Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
    J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.